| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptor Protein-Tyrosine Kinases | 4 | 2018 | 160 | 1.670 |
Why?
|
| Lung Neoplasms | 11 | 2018 | 2370 | 1.090 |
Why?
|
| Glucuronosyltransferase | 7 | 2008 | 186 | 1.020 |
Why?
|
| Exons | 5 | 2018 | 453 | 0.900 |
Why?
|
| Alternative Splicing | 2 | 2018 | 212 | 0.670 |
Why?
|
| Vitamin D Deficiency | 6 | 2018 | 104 | 0.670 |
Why?
|
| Sequence Analysis, RNA | 2 | 2018 | 241 | 0.660 |
Why?
|
| Extracellular Space | 1 | 2017 | 92 | 0.580 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 919 | 0.570 |
Why?
|
| Protein Isoforms | 1 | 2017 | 278 | 0.550 |
Why?
|
| Proto-Oncogene Proteins c-met | 6 | 2010 | 199 | 0.540 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 869 | 0.460 |
Why?
|
| Serotonin | 3 | 2005 | 221 | 0.460 |
Why?
|
| Trigonella | 1 | 2012 | 1 | 0.420 |
Why?
|
| Leukemia, T-Cell | 1 | 2012 | 17 | 0.420 |
Why?
|
| Lymphoma, T-Cell | 1 | 2012 | 55 | 0.400 |
Why?
|
| Calcitriol | 1 | 2013 | 173 | 0.400 |
Why?
|
| Vitamin D | 5 | 2018 | 269 | 0.390 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2015 | 2415 | 0.380 |
Why?
|
| Phytotherapy | 1 | 2012 | 136 | 0.380 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 274 | 0.360 |
Why?
|
| Insulin Resistance | 1 | 2013 | 353 | 0.360 |
Why?
|
| Autophagy | 1 | 2012 | 159 | 0.360 |
Why?
|
| Plant Extracts | 1 | 2012 | 245 | 0.360 |
Why?
|
| Cell Line, Tumor | 8 | 2018 | 2587 | 0.360 |
Why?
|
| Glucuronides | 5 | 2008 | 34 | 0.360 |
Why?
|
| Liver | 4 | 2013 | 1211 | 0.300 |
Why?
|
| Saudi Arabia | 9 | 2019 | 16 | 0.290 |
Why?
|
| Pregnancy Trimester, First | 2 | 2018 | 63 | 0.280 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2015 | 112 | 0.280 |
Why?
|
| Hydroxytryptophol | 1 | 2004 | 1 | 0.240 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2005 | 154 | 0.230 |
Why?
|
| ErbB Receptors | 4 | 2011 | 499 | 0.220 |
Why?
|
| Obesity | 4 | 2014 | 972 | 0.210 |
Why?
|
| Humans | 33 | 2019 | 89970 | 0.200 |
Why?
|
| Body Mass Index | 3 | 2014 | 776 | 0.180 |
Why?
|
| Paxillin | 2 | 2013 | 58 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2018 | 2363 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2015 | 1131 | 0.170 |
Why?
|
| Receptors, Growth Factor | 2 | 2010 | 52 | 0.170 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2019 | 7 | 0.160 |
Why?
|
| Transcription, Genetic | 2 | 2013 | 1158 | 0.150 |
Why?
|
| Diabetes, Gestational | 1 | 2018 | 41 | 0.150 |
Why?
|
| Dietary Supplements | 1 | 2018 | 124 | 0.140 |
Why?
|
| Biomarkers | 5 | 2019 | 1778 | 0.140 |
Why?
|
| Pharmacogenetics | 3 | 2005 | 437 | 0.140 |
Why?
|
| Child | 8 | 2019 | 7244 | 0.130 |
Why?
|
| Adolescent | 9 | 2018 | 9342 | 0.130 |
Why?
|
| Male | 16 | 2018 | 42682 | 0.130 |
Why?
|
| Dairy Products | 1 | 2015 | 11 | 0.130 |
Why?
|
| Child, Preschool | 5 | 2005 | 3773 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 3 | 2015 | 961 | 0.120 |
Why?
|
| Sequence Deletion | 1 | 2015 | 205 | 0.120 |
Why?
|
| Dyslipidemias | 1 | 2015 | 107 | 0.120 |
Why?
|
| Parathyroid Hormone | 1 | 2015 | 220 | 0.110 |
Why?
|
| Adult | 13 | 2018 | 26822 | 0.110 |
Why?
|
| Genotype | 3 | 2009 | 1853 | 0.110 |
Why?
|
| Oxazepam | 2 | 2004 | 3 | 0.110 |
Why?
|
| Middle Aged | 11 | 2018 | 26148 | 0.110 |
Why?
|
| Microsomes, Liver | 2 | 2004 | 49 | 0.110 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2013 | 17 | 0.110 |
Why?
|
| Calcium | 2 | 2015 | 1179 | 0.110 |
Why?
|
| Indoles | 3 | 2009 | 300 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 539 | 0.110 |
Why?
|
| Piperazines | 3 | 2009 | 283 | 0.110 |
Why?
|
| Receptor, Insulin | 1 | 2013 | 54 | 0.110 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2013 | 55 | 0.110 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 288 | 0.110 |
Why?
|
| Eugenol | 1 | 2012 | 2 | 0.110 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 2012 | 3 | 0.110 |
Why?
|
| Guaiacol | 1 | 2012 | 3 | 0.110 |
Why?
|
| Benzaldehydes | 1 | 2012 | 4 | 0.110 |
Why?
|
| Sesquiterpenes | 1 | 2012 | 12 | 0.110 |
Why?
|
| Female | 15 | 2018 | 46595 | 0.110 |
Why?
|
| Catechols | 1 | 2012 | 9 | 0.110 |
Why?
|
| Fatty Alcohols | 1 | 2012 | 10 | 0.100 |
Why?
|
| Tissue Distribution | 1 | 2013 | 293 | 0.100 |
Why?
|
| Substrate Specificity | 2 | 2004 | 352 | 0.100 |
Why?
|
| Jurkat Cells | 1 | 2012 | 77 | 0.100 |
Why?
|
| Sulfonamides | 3 | 2009 | 319 | 0.100 |
Why?
|
| Muscles | 1 | 2013 | 193 | 0.100 |
Why?
|
| Vacuoles | 1 | 2012 | 46 | 0.100 |
Why?
|
| Pregnancy Complications | 1 | 2015 | 345 | 0.100 |
Why?
|
| Seeds | 1 | 2012 | 51 | 0.100 |
Why?
|
| Focal Adhesions | 1 | 2013 | 70 | 0.100 |
Why?
|
| Mitochondrial Dynamics | 1 | 2013 | 56 | 0.100 |
Why?
|
| Calcifediol | 1 | 2012 | 20 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1452 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 313 | 0.100 |
Why?
|
| Sunlight | 1 | 2012 | 28 | 0.100 |
Why?
|
| Diet, High-Fat | 1 | 2013 | 119 | 0.100 |
Why?
|
| Receptors, Calcitriol | 1 | 2013 | 130 | 0.100 |
Why?
|
| Calcium, Dietary | 1 | 2012 | 64 | 0.100 |
Why?
|
| Body Weight | 1 | 2013 | 453 | 0.100 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2012 | 184 | 0.100 |
Why?
|
| Aged | 7 | 2012 | 19254 | 0.090 |
Why?
|
| DNA Mutational Analysis | 2 | 2009 | 529 | 0.090 |
Why?
|
| Adipose Tissue | 1 | 2013 | 262 | 0.090 |
Why?
|
| Cell Line | 2 | 2012 | 2495 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 346 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2010 | 36 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2012 | 726 | 0.090 |
Why?
|
| Semaphorins | 1 | 2009 | 17 | 0.080 |
Why?
|
| Animals | 8 | 2014 | 27528 | 0.080 |
Why?
|
| RNA, Small Interfering | 4 | 2014 | 557 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2012 | 665 | 0.080 |
Why?
|
| Cross-Sectional Studies | 4 | 2018 | 1730 | 0.080 |
Why?
|
| PAX5 Transcription Factor | 1 | 2009 | 33 | 0.080 |
Why?
|
| Exercise | 1 | 2012 | 328 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 1929 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 684 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2010 | 281 | 0.080 |
Why?
|
| Vulva | 1 | 2008 | 23 | 0.080 |
Why?
|
| Germ-Line Mutation | 1 | 2011 | 347 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2008 | 78 | 0.070 |
Why?
|
| Mutation | 5 | 2013 | 4168 | 0.070 |
Why?
|
| Risk Factors | 5 | 2018 | 5559 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 217 | 0.070 |
Why?
|
| Phenotype | 3 | 2015 | 2458 | 0.070 |
Why?
|
| Nutritional Status | 2 | 2018 | 81 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 644 | 0.070 |
Why?
|
| Prevalence | 3 | 2015 | 1250 | 0.070 |
Why?
|
| Mice | 4 | 2014 | 11851 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 716 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 3252 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2012 | 1098 | 0.060 |
Why?
|
| Prognosis | 2 | 2012 | 3798 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 1180 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2008 | 1008 | 0.060 |
Why?
|
| Isoenzymes | 2 | 2003 | 274 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2008 | 2026 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2009 | 1315 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 586 | 0.060 |
Why?
|
| Rats, Gunn | 1 | 2004 | 2 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 825 | 0.060 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2004 | 14 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2004 | 105 | 0.060 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2004 | 19 | 0.060 |
Why?
|
| Cats | 1 | 2004 | 305 | 0.060 |
Why?
|
| Bupropion | 1 | 2004 | 21 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2004 | 44 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2012 | 1545 | 0.060 |
Why?
|
| Rats, Wistar | 1 | 2004 | 303 | 0.060 |
Why?
|
| Gene Dosage | 3 | 2009 | 210 | 0.060 |
Why?
|
| Triglycerides | 2 | 2015 | 233 | 0.060 |
Why?
|
| Microsomes | 1 | 2003 | 35 | 0.050 |
Why?
|
| Haplotypes | 1 | 2005 | 637 | 0.050 |
Why?
|
| Anti-Anxiety Agents | 1 | 2002 | 23 | 0.050 |
Why?
|
| Insecta | 1 | 2003 | 49 | 0.050 |
Why?
|
| Cholesterol | 2 | 2015 | 360 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2018 | 2655 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2009 | 1061 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2004 | 328 | 0.050 |
Why?
|
| Young Adult | 3 | 2018 | 6410 | 0.050 |
Why?
|
| Sex Factors | 2 | 2015 | 1075 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2015 | 305 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2014 | 485 | 0.040 |
Why?
|
| Immunoblotting | 2 | 2012 | 272 | 0.040 |
Why?
|
| Transfection | 2 | 2014 | 909 | 0.040 |
Why?
|
| Pregnancy | 2 | 2018 | 3048 | 0.040 |
Why?
|
| Vitamin B 12 | 1 | 2019 | 24 | 0.040 |
Why?
|
| Age Factors | 2 | 2015 | 1880 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 6783 | 0.040 |
Why?
|
| Fitness Centers | 1 | 2018 | 1 | 0.040 |
Why?
|
| Rats | 1 | 2004 | 4048 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2018 | 227 | 0.040 |
Why?
|
| Fasting | 1 | 2018 | 162 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2012 | 899 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 2331 | 0.030 |
Why?
|
| RNA Interference | 2 | 2008 | 376 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2009 | 740 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 682 | 0.030 |
Why?
|
| Parents | 1 | 2019 | 290 | 0.030 |
Why?
|
| Recommended Dietary Allowances | 1 | 2015 | 2 | 0.030 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 1 | 2015 | 3 | 0.030 |
Why?
|
| Protective Factors | 1 | 2015 | 23 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 596 | 0.030 |
Why?
|
| Endoglin | 1 | 2014 | 21 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2014 | 85 | 0.030 |
Why?
|
| Eating | 1 | 2015 | 167 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2018 | 837 | 0.030 |
Why?
|
| Random Allocation | 1 | 2014 | 327 | 0.030 |
Why?
|
| Apoptosis | 2 | 2012 | 1718 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 259 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2014 | 307 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1603 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2014 | 211 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2015 | 687 | 0.030 |
Why?
|
| Ligands | 1 | 2014 | 447 | 0.030 |
Why?
|
| Kinetics | 2 | 2008 | 1534 | 0.030 |
Why?
|
| Lipocalin-2 | 1 | 2012 | 37 | 0.030 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2012 | 25 | 0.030 |
Why?
|
| Lipocalins | 1 | 2012 | 35 | 0.030 |
Why?
|
| Acute-Phase Proteins | 1 | 2012 | 37 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2014 | 466 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2015 | 328 | 0.030 |
Why?
|
| Diet Surveys | 1 | 2012 | 20 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 280 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 161 | 0.020 |
Why?
|
| Carcinoma, Large Cell | 1 | 2012 | 39 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 294 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 126 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2012 | 168 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 303 | 0.020 |
Why?
|
| Health Surveys | 1 | 2012 | 240 | 0.020 |
Why?
|
| Taiwan | 1 | 2011 | 24 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 421 | 0.020 |
Why?
|
| Allelic Imbalance | 1 | 2011 | 22 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 646 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2014 | 3404 | 0.020 |
Why?
|
| Overweight | 1 | 2012 | 119 | 0.020 |
Why?
|
| Peptides | 1 | 2014 | 649 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2014 | 407 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2010 | 78 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 106 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2010 | 86 | 0.020 |
Why?
|
| Wound Healing | 1 | 2012 | 361 | 0.020 |
Why?
|
| Cell Survival | 1 | 2012 | 983 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2011 | 341 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1130 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 283 | 0.020 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2009 | 34 | 0.020 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2009 | 24 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 543 | 0.020 |
Why?
|
| Paired Box Transcription Factors | 1 | 2009 | 52 | 0.020 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2009 | 33 | 0.020 |
Why?
|
| Deoxycholic Acid | 1 | 2008 | 10 | 0.020 |
Why?
|
| CDX2 Transcription Factor | 1 | 2008 | 7 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 1 | 1 | 2008 | 30 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 786 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2008 | 66 | 0.020 |
Why?
|
| Rifampin | 1 | 2008 | 23 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 793 | 0.020 |
Why?
|
| Receptors, Steroid | 1 | 2008 | 42 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2008 | 16 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 247 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 690 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2009 | 352 | 0.020 |
Why?
|
| Bile Acids and Salts | 1 | 2008 | 67 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2008 | 183 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 308 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2008 | 277 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2008 | 645 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2009 | 816 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2008 | 294 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 4331 | 0.020 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2008 | 135 | 0.020 |
Why?
|
| Cisplatin | 1 | 2009 | 598 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 194 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2009 | 602 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1867 | 0.020 |
Why?
|
| Nicotine | 1 | 2008 | 200 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2012 | 784 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 2329 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 569 | 0.020 |
Why?
|
| Caenorhabditis elegans | 1 | 2008 | 231 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 744 | 0.020 |
Why?
|
| Lung | 1 | 2012 | 1292 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 1185 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 1801 | 0.010 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2004 | 6 | 0.010 |
Why?
|
| Hydroxylation | 1 | 2004 | 17 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 559 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 1284 | 0.010 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2002 | 44 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 2002 | 102 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2002 | 315 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2008 | 1669 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2002 | 996 | 0.010 |
Why?
|
| Alleles | 1 | 2002 | 1139 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 2506 | 0.010 |
Why?
|
| Algorithms | 1 | 2002 | 1913 | 0.010 |
Why?
|
| Neoplasms | 1 | 2009 | 3065 | 0.010 |
Why?
|